Navigation Links
Beckman Coulter Announces First Quarter 2009 Results
Date:4/28/2009

profit decreased 3% to $319.1 million, gross margin increased 100 basis points to 46.1% versus first quarter 2008 due to favorable product mix.

Operating income was $39.6 million. On an adjusted basis, operating income increased to $66 million, or 9.5% of sales. Cost containment initiatives, which began in 2008, effectively drove a 5% decrease in adjusted operating expense versus prior year quarter. Adjusted non-operating expense was $9.6 million.

The adjusted tax rate in the quarter was 19.3%, as compared to 23.9% in prior year quarter. The favorable adjusted tax rate is due to discrete items in the quarter. Net earnings were $20.6 million or $0.32 per fully diluted share, including the $0.03 non-cash charge to interest expense due to new accounting rules governing convertible debt instruments. Adjusting for special items but including interest expense associated with the accounting change, net earnings were $45.5 million or $0.71 per fully diluted share.

Garrett stated, "In the quarter, we continued to realize strong cash instrument sales in Asia Pacific. Cash instruments sales in other major geographies decreased as the current economic environment caused customers to be cautious in their capital spending. Extremely strong cash instrument sales throughout 2008 will make for a difficult comparison in 2009. A product mix favoring higher margin recurring revenue and a sharp focus on operating expense management should allow us to deliver on our earnings goals."

Recent Developments

  • Introduced the Gallios flow cytometer for the research market, the first in a series of cytometry product introductions in 2009. When combined with the company's broad reagent offering, new cytometry products provide a powerful solution for cellular analysis, increasing productivity and improving the reliability of results.
  • Declared a $0.17 per share quarter
    '/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes
2. Beckman Coulter to Webcast Annual Stockholders Meeting
3. Beckman Coulter to Acquire Lab-Based Diagnostics Business From Olympus Corporation
4. Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
5. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
6. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
7. Beckman Coulter to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. Beckman Coulter to Host Annual Business Review
9. Beckman Coulter to Present at Upcoming Healthcare Conferences
10. Beckman Coulter to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
11. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been ... comes with a second treatment cup to help prevent and ... cup is thinner on the edges for a softer contact ... and uneven surfaces on the face, neck and décolleté. Choose ... on areas such as the cheeks and neck, or opt ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
(Date:7/10/2014)... D.C., June 17, 2014 Using microscopic polymer ... specific gases, researchers at MIT,s Quantum Photonics Laboratory ... levels in the parts-per-billion range. Optical sensors are ... their high signal-to-noise ratio, compact, lightweight nature, and ... gas sensors had been developed before, the MIT ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2
... Palatin Technologies, Inc. (NYSE Amex: PTN ... clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor ... the treatment of obesity. AZD2820 is a clinical candidate ... Palatin Technologies. Obesity is a global problem, ...
... 4, 2011   ReportsnReports announces ... Hospital-Acquired Infections (HAI) Diagnostics Market in its store ... for Alternatives to Needle-Based Systems for Vaccine and Biologics ... a focal point of competition within the pharmaceutical industry. The ...
... coatings devised by researchers from the National Institute of ... conventional flame retardants used in the polyurethane foam of ... and perhaps by as much as 1,130 percent. ... Polymer ,* suggest that significant fire-safety advantages can be ...
Cached Biology Technology:Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 2ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 4Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:7/10/2014)... 2, 2014  Unisys Corporation,s (NYSE: UIS ) ... N.V., today announced that it has been selected by the ... a new Basic Provision Biometrics solution for penitentiaries across ... the contract with a solution based on its open standards-based ... of the contract is up to seven years, with the ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... The ability to shrink laboratory-scale processes to automated ... example, inexpensive and highly portable devices that process ... anthrax are needed by the U.S. military and ... of "lab-on-a-chip" technology is the need for miniaturized ...
... from reproductive biologists at the University of Massachusetts Amherst, with ... sperm capacitation that may one day improve success rates of ... problems, and may eventually lead to a male contraceptive. ... down the road, says Pablo Visconti, lead UMass Amherst author, ...
... review suggests that omega-3 fatty acids taken in excess could ... standards based on the best available evidence need to be ... years ago may not be as clear cut as we ... Public Health and Human Sciences and a coauthor on the ...
Cached Biology News:Super-thin membranes clear the way for chip-sized pumps 2Reproductive biologists move in vitro fertilization knowledge forward 2Reproductive biologists move in vitro fertilization knowledge forward 3Excess omega-3 fatty acids could lead to negative health effects 2Excess omega-3 fatty acids could lead to negative health effects 3
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
... perform 96 assays on four slides. The ... slides with 96 (6mm x 7mm) individual ... expression, or screening analysis studies. Unlike other ... gasket, eliminating the presence of contaminating adhesives. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
... Macro-Prep ion exchange media are rigid ... allows high flow rates at moderate pressures, ... ionic sites, and the hydrophilic matrix reduces ... a high-capacity strong anion exchanger with very ...
Biology Products: